Long before a fortune appears in a ranking, a leader chooses where to concentrate attention. Zhong Shanshan made that choice around Nongfu Spring and Wantai Biological. The result now carries an obligation that early-stage entrepreneurship does not: the business must perform while it renews itself. Zhong Shanshan Built a Fortune on Two Things China Cannot Do Without is a way of asking whether the organization can keep its edge once scale, public expectations and legacy all arrive at the same time.
The record behind the public profile is unusually instructive. Zhong Shanshan is the founder and chairman of Nongfu Spring, a bottled water company that listed its shares in Hong Kong in 2020. Hangzhou-born Zhong dropped out of elementary school during China's chaotic Cultural Revolution.
The wealth associated with Zhong Shanshan is rooted in beverages, pharmaceuticals, but that label is too narrow for the leadership story. Nongfu Spring and Wantai Biological sits within food & beverage, a field where strategic control is created through a series of linked choices rather than one transaction. The advantage has to be renewed in operations: who gets capital, which customers shape the roadmap, what remains proprietary and where the organization accepts dependence on a partner. For Zhong Shanshan, those choices now carry more weight than the origin story because the business has become part of the market infrastructure around it.
From advantage to institution
Food fortunes are built on repetition: the same purchase, made by millions of households, week after week. That makes distribution and quality control more valuable than spectacle. It also makes reputation unusually fragile. Leaders in the sector must balance pricing power with affordability, secure supply without becoming complacent and build brands that can travel without losing local trust. The apparently ordinary product is only the visible end of an industrial system whose margins depend on exact execution.
The story of Nongfu Spring and Wantai Biological can be read through a sequence of concentrated bets. That history encourages confidence, but it can also make caution look like timidity. Zhong Shanshan faces a more demanding test now: to fund reinvention without forcing every part of the organization to move at the same speed. Capital should follow learning, not reputation. The businesses that can prove customer pull deserve acceleration; the rest should not be protected by the prestige of the group.
The succession question is broader than naming a successor. It is about what must remain stable when leadership changes and what should finally be allowed to change. Nongfu Spring and Wantai Biological needs a clear account of decision rights, incentives and the role of family or founder capital. Zhong Shanshan can shape that architecture while authority is strong. Waiting until transition is unavoidable would turn a strategic choice into a market event, with employees and partners forced to interpret every signal.
He later had jobs as a construction worker, a newspaper reporter and a beverage sales agent before starting his own business. Zhong also controls Wantai Biological, which makes rapid diagnostic tests for infectious diseases including Covid-19. His son Zhong Shu Zi is a non-executive director at Nongfu.
A harder test than expansion
The pressure comes from the same force that created the fortune: scale. A larger system has more purchasing power and political relevance, but it also has more points of failure and more stakeholders able to demand an answer. The next phase will be judged less by expansion announcements than by returns, governance and the ability to absorb a bad year without abandoning the long view.
Investors should resist turning Zhong Shanshan into a symbol. Symbols are easy to admire or attack; businesses require comparison. The relevant questions for Nongfu Spring and Wantai Biological are concrete. Is return on new capital holding up? Is growth creating cash or consuming it? Are adjacent businesses strengthening the core or borrowing its reputation? The answers will matter more than a single market move because they show whether leadership is converting influence into an operating advantage competitors cannot purchase quickly.
Operational discipline becomes most valuable when conditions are favorable, because that is when weak commitments are easiest to hide. Zhong Shanshan can use the current position of Nongfu Spring and Wantai Biological to simplify reporting lines, retire marginal projects and strengthen the parts of the network customers cannot see. None of that will produce the loudest announcement. It will, however, determine how quickly the organization can respond when supply, regulation or demand moves in a direction the annual plan did not anticipate.
The geography of influence
East Asia adds a particular strategic pressure. Dense supply chains and demanding domestic customers can accelerate learning, while trade controls and political friction can narrow the room to maneuver. Zhong Shanshan has to build relationships that survive policy cycles and localize enough capability to remain trusted without fragmenting Nongfu Spring and Wantai Biological into inefficient national versions. The region rewards speed, but the global opportunity belongs to companies that can translate speed into standards others choose to adopt. From China, Zhong Shanshan also has to decide how much of the operating model should travel and how much must remain shaped by the home market.
That is the next act for Zhong Shanshan. The fortune may continue to be measured through the market value attached to Nongfu Spring and Wantai Biological, but leadership will be measured through the quality of the institution left behind: whether it can absorb challenge, allocate capital without nostalgia and stay useful as its industry changes. The point of Zhong Shanshan Built a Fortune on Two Things China Cannot Do Without is not that the outcome is settled. It is that the strategic question is now visible, and the answer will be written by operating decisions rather than mythology.
Banner photograph: Forbes profile image.
